Survival and prognosis following resection of primary non small cell bronchogenic carcinoma

Kadri, Muqueet; Dussek, J E

doi:10.1016/1010-7940(91)90211-2

Cited by 77 publications

(31 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This mortality is 2.5-fold to 4-fold lower than the 26% mortality reported from the Intergroup trial and consistent or slightly higher than other reports of pneumonectomy alone or chemotherapy followed by pneumonectomy (Table 4). 2,3,17,18 The results from this study of a 6% 30-day mortality rate are comparable to our own published data showing a 30-day mortality rate of 4% after pneumonectomy without induction therapy. 19 In addition, only 4 patients in the current series developed fatal pulmonary complications compared with the 11 patients who died as a result of ARDS (21%) in the Intergroup study.…”

Section: Discussionsupporting

confidence: 88%

“…In addition, the overall treatment-related mortality was acceptable at 10%, with pneumonectomy patients having a higher mortality rate (15%), which is consistent with the known increased mortality observed in patients undergoing pneumonectomy compared with lesser resections. 2,3 The results of this trial prompted a North American Intergroup trial evaluating chemoradiation followed by surgery versus chemoradiotherapy alone for patients with stage III NSCLC. This latter trial demonstrated a statically significant reduction in local failure (22% vs 10%; P 5 .002) and improvement in progression-free survival (PFS) (22.4% vs 11.1%; P 5 .017) in patients receiving the trimodality approach without a difference in overall survival.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Pneumonectomy after chemoradiation

Allen

Mentzer

Yeap

et al. 2008

Cancer

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is the most common cancer in children. The current treatment protocol for ALL involves an intense chemotherapy regimen yielding cure rates of nearly 80%. However, new therapies need to be designed not only to increase the survival rate but also to combat the risk of severe therapy associated toxicities including secondary malignancies, growth problems, organ damage, and infertility. The c‐Myb proto‐oncogene is highly expressed in immature hematopoietic cells. In this study, we demonstrate that loss of c‐Myb itself decreased the viability of these leukemic cells. Additionally, the inhibition of c‐Myb caused a decrease in cell proliferation, significantly increased the number of cells in G0/G1 phase of the cell cycle, increased the sensitivity of pre‐B‐ALL cells to cytotoxic agents in vitro, and significantly delayed disease onset in a mouse model of leukemia. Furthermore, we demonstrate that Bcl‐2 is a target of c‐Myb in pre‐B‐ALL cells. Our results identify c‐Myb as a potential therapeutic target in pre‐B‐ALL and suggest that suppression of c‐Myb levels or activity, in combination with currently used therapies and/or dose reduction, may lead to a decrease in toxicity and an increase in patient survival rates. Because c‐Myb is aberrantly expressed in several other malignancies, targeting c‐Myb will have broad clinical applications. Am. J. Hematol., 2012. © 2012 Wiley Periodicals, Inc.

show abstract

Section: Discussionsupporting

confidence: 88%

mentioning

confidence: 99%

Pneumonectomy after chemoradiation

Allen

Mentzer

Yeap

et al. 2008

Cancer

View full text Add to dashboard Cite

show abstract

“…Some recommend different limits for different resections [18]. In spite of this consensus for identifying patients at risk, about 30% develop cardiopulmonary complications with a 30 day mortality of 0.6-5% [18][19][20], depending on the surgical procedure.Both the respiratory and cardiovascular systems are under stress during physical exercise because of the oxygen requirement of working muscles, and carbon dioxide is produced. An increase in this gas exchange implies a close coupling of pulmonary ventilation and cardiovascular circulation.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

Exercise testing in the preoperative evaluation of patients with bronchogenic carcinoma

Larsen¹,

Ug²,

Milman³

et al. 1997

Eur Respir J

View full text Add to dashboard Cite

The aim of this study was to evaluate which parameters of preoperative spirometry and cardiopulmonary exercise test are the best predictors of postoperative morbidity and mortality in patients with bronchogenic carcinoma.Ninety seven patients were prospectively and consecutively examined. All patients had preoperative maximal exercise test and dynamic spirometry. Postoperative complications and causes of death were registered. Logistic regression was used and models explaining the relationship between preoperative variables and postoperative complications and deaths were constructed.We found significant differences in preoperative maximal workload and carbon dioxide output between groups, with and without cardiopulmonary-related complications, but not in spirometry variables. Logistic regression showed maximal workload to be the only predictor of cardiopulmonary complications. Maximal oxygen uptake was predictive of cardiopulmonary deaths. Maximal oxygen uptake and forced expiratory volume were predictive of postoperative complications. A maximal oxygen uptake <50% predicted was associated with high risk of death from cardiopulmonary causes. Kaplan-Meier survival curves showed that maximal oxygen uptake was correlated to long-term survival, while spirometric variables were not.Exercise testing can be used in the preoperative evaluation of patients with nonmetastatic bronchogenic carcinoma. A combination of the results of variables from spirometry and exercise testing is proposed to be used as a preoperative criterion for operability. Eur Respir J 1997; 10: 1559-1565 Carcinoma of the lung is one of the most common causes of death due to cancer in men, and is increasingly common in women. Some 900,000 new cases are reported worldwide every year [1]. The prognosis in untreated cases is poor, and at present the major curative treatment modality for non-small cell carcinoma is resection. The removal of lung parenchyma from patients, who are usually smokers with compromised cardiovascular or pulmonary status, may lead to cardiopulmonary failure or death. Many variables have been used to assess the risk of postoperative complications, but it is not clear which of these parameters in preoperative pulmonary function testing are the best predictors of the operative outcome. Many centres recommend operation without additional testing in patients with a forced expiratory volume in one second (FEV1) >2.0 L or 60% of predicted and a diffusing capacity >60% pred [2][3][4][5][6]. If these requirements are not met, a perfusion or ventilation scan is performed, and the predicted postoperative FEV1 (FEV1,ppo) is estimated. The accuracy of these methods is proven [7][8][9][10][11] and it seems generally accepted that a FEV1,ppo of 0.8-1.0 L or 30% pred represents the lower limits of acceptable risk [4][5][6][12][13][14][15][16][17]. Some recommend different limits for different resections [18]. In spite of this consensus for identifying patients at risk, about 30% develop cardiopulmonary complications with a 30 day mortal...

show abstract

“…No G:C to A:T glycine to aspartic acid transitions were observed in codon 13 using the ARMS technique. All of the mutations were found to be at the second resection (11,12). Thus rapid, early and accurate identification of mutations in the K-ras gene would aid in the diagnosis of lung cancer at a potentially curable stage of the disease.…”

Section: Resultsmentioning

confidence: 97%

Detection of K-Ras Mutations in Nonsmall Cell Lung-Carcinoma

et al. 1995

View full text Add to dashboard Cite

Forty-five non-small cell lung cancers (NSCLC) were examined for the presence of K-ras mutations in codon 12 using RFLP (restriction fragment length polymorphism) and ARMS (amplification refractory mutation system) assays. The RFLP analysis consisted of a PCR and subsequent digestion of the product with BstNI. Three adenocarcinomas and one adenosquamous carcinoma were shown to have mutations at codon 12. All of these samples were also examined using the ARMS assay for mutations at codon 12 and second base G to A transitions at codon 13 of the K-ras gene. The same four samples were confirmed to have a single base change in codon 12. No G to A transitions were found at codon 13. The four mutations were: one G to C transversion, one G to A transition and two G to Τ transversions. All mutations occurred at the second position of codon 12 as shown by the ARMS assay. Both of these techniques are rapid and reproducible for the identification of mutations in the K-ras gene and have potential for use in cancer diagnosis.

show abstract

Survival and prognosis following resection of primary non small cell bronchogenic carcinoma

Cited by 77 publications

References 17 publications

Pneumonectomy after chemoradiation

Pneumonectomy after chemoradiation

Exercise testing in the preoperative evaluation of patients with bronchogenic carcinoma

Detection of K-Ras Mutations in Nonsmall Cell Lung-Carcinoma

Contact Info

Product

Resources

About